- Home
- ANIP
as 01-17-2025 4:00pm EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $77.33 | AVG Volume (30 days): | 254.4K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.50 - $70.81 | Next Earning Date: | 02-27-2025 |
| Revenue: | $555,456,000 | Revenue Growth: | 23.60% |
| Revenue Growth (this year): | 25.48% | Revenue Growth (next year): | 20.24% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Jan 13 '25 | Sell | $53.92 | 400 | $21,568.00 | 55,588 | |
| CAREY STEPHEN P. | ANIP | SVP & CFO | Dec 17 '24 | Sell | $55.79 | 7,500 | $418,425.00 | 154,468 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Dec 13 '24 | Sell | $56.24 | 250 | $14,060.00 | 55,588 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Dec 11 '24 | Sell | $60.00 | 1,000 | $60,000.00 | 49,059 | |
| Lalwani Nikhil | ANIP | PRESIDENT & CEO | Nov 26 '24 | Sell | $58.13 | 33,481 | $1,941,442.30 | 370,378 | |
| Mutz Christopher | ANIP | HEAD OF RARE DISEASE | Nov 15 '24 | Sell | $57.70 | 6,500 | $375,050.00 | 76,777 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Nov 13 '24 | Sell | $61.36 | 250 | $15,340.00 | 55,588 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?
Argus Research
3 days ago
ANIP: What does Argus have to say about ANIP?
PR Newswire
5 days ago
Alcami Announces CEO Transition
MT Newswires
5 days ago
Ani Pharmaceuticals Sees Fiscal 2024 Adjusted EPS, Revenue at or Above Guidance; Sets Fiscal 2025 Revenue Outlook
GlobeNewswire
5 days ago
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
MT Newswires
16 days ago
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
MT Newswires
16 days ago
ANI Pharmaceuticals Launches Generic Version of Motegrity
GlobeNewswire
16 days ago
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.